Agenus Inc. (NASDAQ:AGEN - Free Report)'s stock is scheduled to reverse split on Friday, April 12th. The 1-20 reverse split was announced on Friday, April 12th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, April 12th.
Agenus Price Performance
Agenus stock opened at $0.47 on Tuesday. Agenus has a 52-week low of $0.41 and a 52-week high of $2.13. The firm has a market capitalization of $195.01 million, a P/E ratio of -0.66 and a beta of 1.26. The stock has a fifty day moving average price of $0.64 and a two-hundred day moving average price of $0.75.
Agenus (NASDAQ:AGEN - Get Free Report) last announced its earnings results on Thursday, March 14th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.11). The firm had revenue of $83.80 million during the quarter, compared to the consensus estimate of $54.21 million. On average, equities research analysts predict that Agenus will post -0.41 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on the company. B. Riley decreased their price target on Agenus from $6.00 to $5.00 and set a "buy" rating on the stock in a report on Monday, March 18th. StockNews.com upgraded Agenus from a "sell" rating to a "hold" rating in a report on Sunday, March 24th. Finally, HC Wainwright reiterated a "buy" rating and issued a $8.00 price target on shares of Agenus in a report on Thursday, March 14th.
Get Our Latest Analysis on Agenus
Insider Buying and Selling
In related news, insider Garo H. Armen bought 500,000 shares of the business's stock in a transaction dated Thursday, February 15th. The stock was bought at an average price of $0.65 per share, for a total transaction of $325,000.00. Following the purchase, the insider now owns 625,969 shares in the company, valued at approximately $406,879.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.80% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Agenus
A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in Agenus by 12.4% during the fourth quarter. Vanguard Group Inc. now owns 30,266,890 shares of the biotechnology company's stock worth $25,058,000 after acquiring an additional 3,328,451 shares during the period. BlackRock Inc. increased its position in Agenus by 15.9% during the second quarter. BlackRock Inc. now owns 27,180,109 shares of the biotechnology company's stock worth $43,488,000 after acquiring an additional 3,724,892 shares during the period. State Street Corp increased its position in Agenus by 15.7% during the first quarter. State Street Corp now owns 26,154,127 shares of the biotechnology company's stock worth $39,754,000 after acquiring an additional 3,550,477 shares during the period. Finally, Point72 Asset Management L.P. increased its position in Agenus by 124.7% during the second quarter. Point72 Asset Management L.P. now owns 17,616,983 shares of the biotechnology company's stock worth $28,187,000 after acquiring an additional 9,776,083 shares during the period. 61.46% of the stock is owned by institutional investors.
About Agenus
(
Get Free Report)
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Featured Stories
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
